Abstract
Type II natural killer T (NKT) cells in cancer immunity are typically associated with suppression of tumor immunosurveillance through secretion of IL-13. We previously demonstrated that CpG oligonucleotide therapy activated Type II NKT cells to produce T helper type 1 (Th1) rather than T helper type 2 (Th2) cytokines. This cytokine skewing may manifest in Type II NKT cell antitumor properties in an immunotherapeutic setting.
Original language | English (US) |
---|---|
Article number | e28977 |
Journal | OncoImmunology |
Volume | 3 |
Issue number | 5 |
DOIs | |
State | Published - 2014 |
Keywords
- CD1
- Immunotherapy
- NKT cells
- Tumor immunity
ASJC Scopus subject areas
- Oncology
- Immunology and Allergy
- Immunology